We’re proud of the value we create for all our stakeholders, and strive to communicate our performance in a clear and timely manner. Download the latest reports, or stay up to date on various metrics of our market performance here. If you have any queries not addressed here, please feel free to get in touch with Investor Relations on our Contact page.
Observe Medical ASA was listed on Oslo Børs 4 November 2019. Our ambition is to provide shareholders, analysts and investors simultaneous access to accurate, clear and relevant information. We aim to make all our communication to the financial market available on this web site.
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…
Read moreNOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…
Read moreOslo, 12 May 2020 – Observe Medical ASA (OSE: OBSERV) today released its presentation of the first quarter 2020, including an updated market study indicating a doubling of the potential market value for the company’s first product, Sippi®. The company’s long term revenue ambition for Sippi® is increased accordingly to NOK 500 million. “During the…
Read moreAnnual Report
Quarterly Presentation – Q1
Annual General Meeting
Half-yearly Report
Quarterly Presentation – Q3
Last updated 18 May 2020
| Name | Number of shares | % of top 20 | % of total | Country | |
|---|---|---|---|---|---|
| 1 | NAVAMEDIC ASA | 3 200 000 | 24,30% | 20,86% | Norway |
| 2 | INGERØ REITEN INV. COMPANY AS | 2 916 667 | 22,15% | 19,01% | Norway |
| 3 | UBS SWITZERLAND AG | 1 420 522 | 10,79% | 9,26% | Switzerland |
| 4 | RO, LARS | 1 300 000 | 9,87% | 8,47% | Norway |
| 5 | ALPINE CAPITAL AS | 645 000 | 4,90% | 4,20% | Norway |
| 6 | ARTAL AS | 560 067 | 4,25% | 3,65% | Norway |
| 7 | SOLEGLAD INVEST AS | 541 668 | 4,11% | 3,53% | Norway |
| 8 | TRANBERGKOLLEN INVEST AS | 491 666 | 3,73% | 3,20% | Norway |
| 9 | LEIKERANE AS | 466 666 | 3,54% | 3,04% | Norway |
| 10 | NORDA ASA | 407 829 | 3,10% | 2,66% | Norway |
| 11 | LAPAS AS | 266 000 | 2,02% | 1,73% | Norway |
| 12 | KRAEBER VERWALTUNG GMBH | 214 850 | 1,63% | 1,40% | Germany |
| 13 | BUKKEVIK INVESTERING AS | 140 000 | 1,06% | 0,91% | Norway |
| 14 | LID, OLAV TARJEI HIORTH | 114 500 | 0,87% | 0,75% | Norway |
| 15 | MK PENSJON PK | 100 025 | 0,76% | 0,65% | Norway |
| 16 | EILERAAS, KARL ANSKAR | 86 491 | 0,66% | 0,56% | Norway |
| 17 | GINNY INVEST AS | 83 349 | 0,63% | 0,54% | Norway |
| 18 | BJØRNTVEDT, VEGARD | 75 080 | 0,57% | 0,49% | Norway |
| 19 | BJØRNTVEDT, EIVIND | 71 076 | 0,54% | 0,46% | Norway |
| 20 | GRAFISK PAPIR AS | 65 000 | 0,49% | 0,42% | Norway |
| Total numer owned by top 20 | 13 166 456 | 100,00% | 85,82% | ||
| Total number of shares | 15 342 673 |
Stock Exchange:
Ticker:
First day of listing:
Sector:
Trading Currency:
ISIN:
Number of shares issued:
Nominal value:
Oslo Axess
OBSERV
4 November 2019
Healthcare
NOK
NO0010865009
15 342 673
NOK 0.26
26 May 2020: Notice of Extraordinary General Meeting on 16 June 2020
26 May 2020: Attendance to the Extraordinary General Meeting on 16 June 2020
24 October 2019: Extraordinary General Meeting
1 October 2019: Extraordinary General Meeting
5 August 2019: Extraordinary General Meeting
Observe Medical ASA per 21 january 2020
The Articles of Association provide for a nomination committee composed of two or three members. The current members of the nomination committee are Bernt Olav Røttingsnes (chair) and Grete Hogstad.
The nomination committee is responsible for nominating candidates for the election of shareholder-elected members and chairperson to the Board of Directors and for nominating members to the nomination committee, as well as making recommendations for remuneration of these.
For nomination committee please contact:
Björn Larsson, Chief Executive Officer
+46 766 201 725 / bjorn.larsson@observemedical.com